The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study
Open Access
- 1 January 2016
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 18 (1) , 22-28
Abstract
Background: The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. Research Design and Methods: Patients with glycated hemoglobin (HbA 1c ) levels of ≥8% (64 mmol/mol) and ≤12% (108 mmol/mol) despite insulin doses of 0.7–1.8 U/kg/day via MDI were randomized to CSII ( n =168) or continued MDI ( n =163). Changes in glucose profiles were evaluated using continuous glucose monitoring data collected over 6-day periods before and 6 months after randomization. Results: After 6 months, reductions in HbA 1c levels were significantly greater with CSII (−1.1±1.2% [−12.0±13.1 mmol/mol]) than with MDI (−0.4±1.1% [−4.4±12.0 mmol/mol]) ( P 180 mg/dL (−12.4%; P =0.0004) and SG >250 mg/dL (−5.5%; P =0.0153), and more time in the SG range of 70–180 mg/dL (12.3%; P =0.0002), with no differences in exposure to SG180 mg/dL were significantly greater with CSII than with MDI after breakfast (−775.9±1,441.2 mg/dL/min vs. −160.7±1,074.1 mg/dL/min; P =0.0015) and after dinner (−731.4±1,580.7 mg/dL/min vs. −71.1±1,083.5 mg/dL/min; P =0.0014). Conclusions: In patients with suboptimally controlled type 2 diabetes, CSII significantly improves selected glucometrics, compared with MDI, without increasing the risk of hypoglycemia.Keywords
This publication has 29 references indexed in Scilit:
- Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trialThe Lancet, 2014
- OpT2mise: A Randomized Controlled Trial to Compare Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 2 Diabetes—Research Design and MethodsDiabetes Technology & Therapeutics, 2014
- Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task ForceEndocrine Practice, 2014
- Transitory Beneficial Effects of Professional Continuous Glucose Monitoring on the Metabolic Control of Patients with Type 1 DiabetesDiabetes Technology & Therapeutics, 2014
- HbA1c: A Review of Analytical and Clinical AspectsAnnals of Laboratory Medicine, 2013
- Insulin Pump for Type 2 DiabetesDiabetes Care, 2013
- Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP)Diabetes Technology & Therapeutics, 2013
- Continuous Glucose Monitoring in 2012Diabetes Technology & Therapeutics, 2013
- Effectiveness of Intensive Insulin Therapy by Multiple Daily Injections and Continuous Subcutaneous Infusion: A Comparison Study in Type 2 Diabetes with Conventional Insulin Regimen FailureHormone and Metabolic Research, 2007
- Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patientsDiabetic Medicine, 2005